HSP90B1 and breast carcinoma: Based on a strategy that combined library screening of purine-scaffold compounds and structural studies, GRP94-specific inhibitors, PU-WS13, PU-H39, and PU-H54, were developed, and these inhibitors significantly induced apoptosis of human HER2 positive breast cancer cells (56).